Background: Despite the current Centers for Medicare and Medicaid Services coverage criteria for carotid artery stenting (CAS), consensus regarding its appropriateness in patients with carotid artery stenosis has not been reached. This is one of the first population-based studies to use a dedicated administrative convention for the endovascular procedure to address whether there is a cohort of patients in whom CAS is more beneficial than carotid endarterectomy (CEA). Methods: We analyzed in-hospital mortality, postoperative stroke, and combined postoperative stoke/mortality in 47,752 CAS or CEA hospitalizations, matched by propensity score, in discharge data sets obtained from the states of New York and California for the years 2005 to 2007. Other outcomes included postoperative complications, length of stay, and volume-outcome relationships. Results: For symptomatic patients undergoing CAS, rates were significantly higher for in-hospital mortality (3.7% vs 1.3%) and combined stroke/mortality (8.3% vs 4.6%) compared with CEA. For asymptomatic patients, there was no statistical difference between mortality (0.6% vs 0.4%), stroke (2.0% vs 1.8%), or combined stroke/mortality (2.4% vs 1.9%) across the endovascular and open procedures, respectively. Postoperative respiratory and urinary complications as well as cranial neuropathy were more common after CEA, whereas postoperative complications, including device malfunction and hypotension, were more frequent after CAS. We did not find a volume-outcome relationship for CEA, but one did exist for CAS. Conclusions: In symptomatic patients with carotid artery stenosis, the most appropriate procedure appears to be CEA, whereas CAS appears to be a suitable minimally invasive approach for asymptomatic patients. On the basis of these results and data from recent multicenter randomized trials, the use of CAS in symptomatic patients should be approached with caution. ( J Vasc Surg 2010;52:906-13.)
For decades, carotid endarterectomy (CEA) has been an effective intervention for preventing ischemic strokes due to significant carotid bifurcation disease. With the advent of endovascular treatment by carotid artery stenting (CAS), the optimal method of stroke prevention in the modern era is under considerable debate. Despite the availability of the endovascular procedure for more than a decade, most available data are from nonrandomized studies. Findings in the few prospective trials comparing CEA and CAS have been mixed, with publications supporting and refuting the superiority of the minimally invasive approach. [1] [2] [3] [4] [5] Midterm and long-term results of a multicenter randomized controlled trial performed in the United States concluded that stenting and endarterectomy were equivalent in patients deemed at high risk for surgery. 6, 7 Conversely, a large multicenter European trial was halted during enrollment due to a high stroke rate in symptomatic patients treated endovascularly. 8 Administrative data sets have the advantage of measuring how new technology fares in the community at large rather than at selected centers. However, until the recent adoption of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code specifically designated for CAS, an accurate outcomes analysis was not possible. In this study, we have reviewed the New York and California state discharge databases for years 2005 to 2007. Using propensity analysis to establish matched cohorts of patients treated with CEA and CAS, we compared stroke and mortality rates, complications, length of stay, and volume/outcome relationships for these two interventions. bases contain present on admission (POA) flags for each diagnosis that were used to separate preexisting comorbid conditions from complications that occurred during hospitalization and were chosen for this analysis because they represent a sizeable proportion of the United States' population.
METHODS
Patient population. Patients were selected using the ICD-9-CM procedure code 00.63 for CAS and 38.12 for CEA in the primary or any secondary position. Excluded were hospitalizations with endovascular repair of endocranial vessels (procedure code 39.72 any position) and carotid dissection (primary diagnoses code 443.21). We also excluded patients who underwent another major intervention (coronary artery bypass grafting, mitral or aortic valve replacement) during the same admission because these higher-morbidity procedures were associated more frequently with adverse outcomes when combined with carotid interventions.
Patients were stratified into three groups: (1) overall or total patient population, (2) symptomatic presentation, and (3) asymptomatic presentation. Symptomatic presentation was defined if admitting or primary diagnosis codes, included in Table I , were POA. Critical to the accuracy of this analysis is the proper choice of ICD-9-CM diagnosis codes for the determination of symptomatic carotid stenosis. We began by surveying practitioners about the codes that are used to determine symptomatic or asymptomatic carotid stenosis. To further validate these choices, we then identified a number of symptomatic and asymptomatic patients undergoing carotid intervention through an internal database at New York Presbyterian Hospital and performed a medical record evaluation to determine the ICD-9-CM diagnosis codes that were used to describe their presentation. This process led to the adoption of the symptomatic codes included in Table I . Asymptomatic patients were defined as those without these diagnosis codes present at the time of admission for their carotid procedure.
Baseline comorbidities were defined using a modified Elixhauser coding algorithm. 9 Only POA diagnoses were included as comorbidities. We compared the following comorbidities in the overall, asymptomatic and symptom-atic cohorts for CEA and CAS (primary and any secondary diagnosis): cardiac (congestive heart failure, cardiac arrhythmia, valvular disease, and coronary disease), pulmonary (emphysema, chronic pulmonary diseases, and respiratory failure), neurologic disorder, peripheral vascular disease (PVD), renal disease, hypertension, disorder of lipid metabolism, diabetes, obesity, neck cancer, and other cancer.
The following postoperative complications were categorized and compared between the propensity-matched groups for the open and endovascular procedures (primary and any secondary diagnosis): cardiac, nonvascular neurologic, transient cerebral, respiratory, respiratory infection, urinary infection, procedurally related infection; local complications (bleeding, cranial neuropathy, device/patch complications, including device malfunction for endovascular repair, and device infection for open procedures venous thromboembolic events), and hypotension. Table II (online only) provides a list of ICD-9-CM comorbidities and complication codes.
Mortality and stroke. Mortality, postoperative stroke, and combined postoperative stroke or mortality, or both (stroke/mortality), were evaluated as our primary outcomes. Postoperative stroke was defined if a discharge had the ICD-9-CM code for postoperative stroke (997.02) or if any of the following diagnoses codes were assigned during the hospitalization: hemiplegia (342.90), intracerebral hemorrhage (431) Length of stay. Mean and median lengths of stay (LOS) for CEA and CAS were compared for propensitymatched pairs within the overall, asymptomatic, and symptomatic cohorts. We evaluated LOS for index hospitalizations regardless of outcomes, hospitalizations free of Cerebral embolism with cerebral infarction 434.91
Cerebral artery occlusion, unspecified, with cerebral infarction 435. 8 Other specified transient cerebral ischemias 435.9
Unspecified transient cerebral ischemia: impending cerebrovascular accident; intermittent cerebral ischemia; transient ischemic attack 434.01
Thrombosis of cerebral arteries with cerebral infarction stroke/mortality, and hospitalizations of patients who developed stroke and stroke/mortality. Hospital volume. Annual hospital volumes in the open and endovascular approach were divided into quintiles. Trends in stroke/mortality rates with increasing volume quintiles were evaluated for CAS and CEA using ordinary least-square regression analysis. Confidence intervals for rates were calculated using normal approximation to the binomial distribution. Multivariate models to predict stroke/mortality after CAS or CEA included annual hospital volume in quintiles. Models are shown in Table III (online only).
Statistical analysis. Propensity scores were used to match CAS patients with CEA patients. Propensity analysis is an increasingly common statistical method in large data set comparative research [10] [11] [12] and has been shown to reduce bias in estimates of the treatment effect in observational studies. 13 The propensity score method allows reduction of multiple background characteristics to a single composite characteristic, generates a propensity score, and finally creates balanced cohorts for comparative analysis. It consists of several steps:
• calculation of predicted probability (propensity) of receiving one treatment vs another; • stratification or matching patients from two different treatment groups by propensity score and verification that matching creates balanced cohorts; and • straightforward estimation of the effect of treatment type on the outcomes.
To determine the propensity score, a logistic regression model was developed where the dependent variable was the type of procedure and the independent variables were patient demographics and baseline clinical characteristics. The fit of the propensity model to the data was assessed using the concordance index. 14 Patients who underwent an endovascular procedure were matched 1:1 to patients who had an open approach using individual propensity scores by greedy match algorithm. 15 The results after matching by propensity score are described in Table IV (online only) .
Before matching, CAS and CEA groups differed by baseline characteristics, after matching the CAS and CEA cohorts became balanced, and age was the only significantly different covariate. However, the difference in age between groups was not clinically significant. The differences between matched pairs were evaluated using paired t test for continuous variables, Wilcoxon signed rank test, and the McNemar test for binary data. Statistical analysis was performed using the SAS software (SAS Institute Inc, Cary, NC). Statistical significance was expressed by values of P Ͻ .05.
RESULTS

Patient population.
In New York and California, 6360 hospitalization for CAS and 41,392 for CEA from 2005 through 2007 were analyzed. Demographics and comorbidities for these patients are provided in Table V. Overall, the open cohort had more women (42.93% vs 39.31%), was older (72.57 years vs 71.29 years), and had a higher rate of obesity compared with the endovascular cohort. Alternatively, the CAS group had higher rates of most comorbidities, including hypertension, hyperlipidemia, diabetes, peripheral vascular disease, neck cancer, cardiac, renal, and noncerebrovascular neurologic disor- ders. Certain inequalities were sustained in the asymptomatic cohort; however, statistical significance was lost in the symptomatic group in comparisons of gender and obesity as well as hypertension, hyperlipidemia, diabetes, and PVD. After matching patients by propensity analysis, there were no statistical distinctions in any comorbidities or gender between the open and endovascular groups (Table V) . Asymptomatic presentation. Before their index hospitalization for either procedure, 43,236 patients (91%) were asymptomatic compared with 4516 (9%) symptomatic patients. Before propensity matching, the data showed CAS to be significantly inferior to CEA in terms of stroke (2.05% vs 1.15%, P Ͻ .0001) and stroke/mortality (2.46% vs 1.38%, P Ͻ .0001). After matching 4353 asymptomatic patients who underwent CAS with 4353 asymptomatic patients who underwent CEA, rates were equivalent for mortality (0.55% vs 0.39%, P ϭ .2743), stroke (2.04% vs 1.75% (P ϭ .3026), and stroke/mortality (2.37% vs 1.93%, P ϭ .1579; Table VI ).
In our analysis of complications in matched asymptomatic pairs, CEA had an increased frequency of respiratory complications (2.44% vs 1.38%, P ϭ .0003), urinary catheterrelated complications (1.56% vs 0.44%, P Ͻ .0001), and cranial neuropathy (0.44% vs 0.18%, P ϭ .0343) compared with CAS. Iatrogenic hypotension (3.65% vs 1.24%, P Ͻ .0001) was more common after the endovascular approach. The rates of transient cerebral ischemia (0.32% vs 0.30%, P ϭ .8474) were not significantly different between procedures (Table VII) .
LOS was significantly longer after CEA than after CAS for all asymptomatic hospitalizations (3.29 vs 2.57 days, P Ͻ .0001) and for patients who survived and did not have a stroke before discharge (3.05 vs 2.36 days, P Ͻ .0001). However, there was no statistical difference in LOS between the two procedures in patients with postoperative stroke (11.59 vs 9.13 days, P ϭ .1048) and stroke/mortality (11.98 vs 12.69, P ϭ .1226; Table VIII ). Symptomatic presentation. After matching symptomatic patients by propensity analysis, 543 pairs who underwent CAS or CEA were identified. Mortality was significantly higher in the CAS cohort (3.68%) compared with CEA (1.29%, P ϭ .0124). The rates of stroke for CAS (5.71%) compared with CEA (4.05%) did not reach significance (P ϭ .2164). When stroke and mortality were combined, CAS (8.29%) was considerably inferior to CEA (4.60%, P ϭ .0138; Table VI) .
We found no statistical differences in the rates of postoperative complications between procedures in symptomatic patients, except for nonvascular neurologic complications (2.21% for CAS vs 0.37% for CEA; described in Table  II , online only). Rates of postoperative cranial neuropathy (0.18% vs 0%), transient cerebral ischemia (0.37% vs 0%), device malfunction (1.29% vs 0.36%), and hypotension (2.95% vs 1.29%) did not achieve statistical significance (Table VII) .
For all symptomatic patients, including patients with and without postoperative stroke, LOS was 7.11 days for the endovascular and 7.05 days for the open techniques (P ϭ .6024). LOS for the two interventions remained equivalent in symptomatic patients who did not experience stroke or death. LOS for CEA and CAS did not reach statistical significance for symptomatic patients with postoperative stroke (13.77 vs 7.54 days) or stroke/mortality (13.83 vs 9.22 days; Table VIII) .
Volume and outcome. The distribution of CAS did not appear to significantly differ between the two states included in this analysis. CAS was performed in 113 hospitals in California and in 61 hospitals in New York. A low annual volume of Ͻ25 CAS procedures was noted in 82% of CAS hospitals in California vs 54% in New York.
We were able to demonstrate a volume-outcome relationship for CAS. Continuous improvement in stroke/ mortality rates with increasing volume was observed for endovascular cases (R 2 ϭ0.7326; Fig 1, A) . We found approximately a 1% decrease in stroke/mortality rates for CEA with increasing volume from the first to second quintile. However, we were not able to demonstrate a continuous volume-outcome relationship for the open procedure (R 2 ϭ 0.2744; Fig 1, B) . After adjustment for patient baseline comorbidities, demographics, and year of procedure, we observed improvement in postoperative stroke or mortality with increasing annual CAS hospital volume up to 34 procedures and no volume-outcome relationship for CEA.
DISCUSSION
The outcomes of CAS and CEA have been compared in various trials. Although the indications for CEA are well defined, the indications for CAS remain controversial. The data presented here represent one of the largest direct comparisons of these two techniques to date. This study found that in symptomatic patients, CAS is associated with a statistically significant increased risk of periprocedural death or stroke (8.29%) compared with CEA (4.60%; P ϭ .014). It may be that the differences in outcomes found in symptomatic and asymptomatic patients can be explained by patient anatomy. One could hypothesize that internal manipulation of an unstable plaque in symptomatic patients may predispose them to embolization and stroke, whereas internal manipulation of stable plaque in an asymptomatic patient may not. [16] [17] [18] The mortality rate in the propensity-matched symptomatic cohort was almost three times as high in patients treated endovascularly than in those treated with CEA. The combined stroke/mortality rates revealed an absolute difference of approximately 3.7% favoring CEA. Ironically, at this point in time, the only reimbursed indication for CAS is for high-risk symptomatic patients. Yet, a major European study 8 and now our analysis of two large data sets from the United States reveal that symptomatic carotid stenosis may not be an appropriate indication for CAS. Our finding of a dramatic and significant increased risk of stroke and death in symptomatic patients undergoing CAS repair warrants re-evaluation of the patient population that may indeed benefit from this intervention.
The mortality rate associated with CAS in symptomatic patients was high and in large part contributed to the difference in outcomes between CAS and CEA. This mortality rate is higher than that reported in registries or clinical trials. However, it is important to point out that rigid exclusion criteria are often used to select patients in these trials, whereas similar patients treated in the community are not excluded. Moreover, centers involved in these trials have been selected for expertise, whereas a large number of CAS procedures reported here were performed in low- 19, 20 who queried the Nationwide Inpatient Sample (NIS) for CAS vs CEA, suggesting that these outcomes may reflect what is currently achieved in the community at large. Conversely, there was no statistically significant advantage for either procedure in matched asymptomatic patients, and the absolute difference for all primary outcomes was Ͻ0.5%. When a minimally invasive intervention is compared with conventional surgery, if there is equivalence in outcomes, more often than not the patient's choice is the less invasive procedure. Nevertheless, other relevant factors often affect the choice of a procedure, including its cost, the steepness of the learning curve for the new technology, as well as the availability of skilled interventionalists capable of providing optimal outcomes. The asymptomatic population in this study constituted approximately 91% of the treated patients. Thus, these findings are relevant to a large number of patients who will be treated for carotid artery disease. In most reported series of patients treated for carotid disease, at least two-thirds are asymptomatic. These findings raise the possibility that ongoing randomized controlled trials comparing CAS and CEA may well demonstrate the benefit and safety of CAS repair in the asymptomatic cohort. 21, 22 At minimum, these data suggest that practitioners should feel confident in encouraging active enrollment of asymptomatic patients in current and future trials comparing these two interventions.
There have been previous attempts to use administrative data sets to compare outcomes of CEA and CAS. McPhee et al, 19, 20 using the NIS, reported higher rates of stroke for both asymptomatic and symptomatic patients undergoing CAS. The McPhee study did not use propensity analysis to directly compare patient cohorts. The importance of propensity-matching patients derived from large data sets cannot be overemphasized. In Table V , it is easily recognizable that patients treated with CAS were higher risk than patients treated with CEA. Thus, an unmatched or "apples to oranges" comparison unjustly favored the open procedure because the surgical intervention was performed in a lower-risk cohort.
Also the method used by McPhee et al for defining postoperative stroke was limited to one ICD-9-CM code: 997.02 (iatrogenic postoperative stroke). After careful and detailed examination of individual hospitalizations within our data set, we observed that many patients who developed postoperative neurologic events were not assigned this ICD-9-CM code. To determine postoperative stroke, we used a series of codes (detailed in Methods) that included hemiplegia, intracerebral hemorrhage, cerebral embolism with infarction, cerebral artery occlusion with infarction, and aphasia.
Lastly, compared with the McPhee analysis, the POA status, available in the New York and California data sets, allows assurance that these events were new and not present before the intervention. POA flags have been used by California and New York for many years and have recently become a requirement by Centers for Medicare and Medicaid Services for all states. However, the POA indicator is not available in the NIS database.
The results of the randomized clinical Carotid Revascularization Endarterectomy vs. Stent Trial (CREST) trial have recently been presented, but a publication of the data is not yet available. These results suggest that CAS may be equivalent to CEA when a combined end point is used that includes stroke, death, and myocardial infarction. 23 These data, once they are available for further scrutiny, may confirm our findings, at least for asymptomatic patients.
As might be anticipated, the incidence of complications was procedure-specific. CEA patients had significantly higher rates of respiratory, venous thromboembolic, and catheter-related complications. The increased incidence of these complications may be related to intubation, greater immobility, and Foley catheter placement, which all occur more frequently in the open procedure. Predictably, cranial neuropathy was also more common after CEA. Alternatively, device/patch complications and hypotension were more common in patients treated with CAS. The latter complication is a well-recognized event that coincides with balloon dilatation of the carotid artery sinus.
Practitioners often think that the LOS for CEA is 1 day and similar to that of CAS. In clinical practice, however, the mean LOS in all comers appears to be Ͼ1 day for both procedures and is significantly longer after CEA. For patients who did not experience stroke or death, this difference was small, on average approximately 1 day. The increased LOS in the overall cohort for the open procedure was particularly evident in patients who sustained a stroke.
The findings of this study need to be considered within the context of previously reported randomized trials. In the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial, the outcomes of CAS and CEA were equivalent at medium-term and long-term follow-up in a mixed cohort of symptomatic and asymptomatic patients. 6, 7 Conversely, the Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S) 8 trial, which included only symptomatic patients, was terminated early secondary to a high rate of stroke in the endovascular cohort. The Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy (SPACE) trial, which randomized symptomatic patients to open or endovascular repair, failed to prove noninferiority of CAS compared with CEA at 30 days, whereas outcomes were equivalent after 2 years of follow-up. 24, 25 Thus, despite the conclusions of three randomized trials, the indications for endovascular repair remain unclear. It should be noted that these three trials enrolled a combined number of 2075 patients, whereas the current study evaluated the outcomes of almost 48,000 patients treated for carotid stenosis, including Ͼ6000 who received stents (albeit, after matching by propensity score, we have 8706 asymptomatic and 1086 symptomatic patients).
Our analysis of the hospital volume/outcome relationship for CAS reveals that increasing hospital volumes are associated with a reduction in the risk of stroke and mortality. These results suggest that CAS is a technically challenging procedure and its performance should be limited to institutions with considerable experience. Conversely, we were not able to demonstrate a substantial relationship between CEA outcomes and volume. Although CEA may be an equally technically challenging intervention, the widespread use and longevity of this procedure appear to have made the volume requirements less rigorous. Furthermore, the volume outcome relationship for carotid stenting may be more significant for symptomatic patients; however, we were unable to make this determination secondary to the low number of outcomes per quintile when symptomatic patients were stratified by volume.
Studies that use administrative data sets have a number of limitations. There is the potential for coding errors. However, because this analysis is a comparison of outcomes for two procedures, we have assumed that the frequency of coding errors will be similar between the two interventions, allowing the comparison to remain valid.
There are also the complexities involved in differentiating complications or outcomes from preexisting disease. Regarding this issue, New York and California data sets allow preoperative and postoperative events to be differentiated, whereas the NIS and other national databases do not. The data that we have acquired are from only two states; however, these two states represent approximately 19% of the United States population. 26 One significant limitation of this analysis is our inability to determine the severity of comorbid or postoperative complications including stroke.
We used the propensity score technique to create balanced cohorts for analysis. A limitation of propensity analysis is that this method, unlike randomization in clinical trials, can only adjust for observed confounding covariates and cannot adjust for unobserved confounders. Therefore, propensity analysis reduces but does not eliminate bias in observational studies. Although propensity analysis allows matching of variables that are available in large administrative data sets, these data sets have limited information about patients who are at high anatomic risk. Thus, we were unable to match patients who were treated for restenosis after previous CEA, contralateral occlusion, hostile neck, or a high bifurcation.
Moreover, long-term outcomes could not be addressed in this analysis because information beyond hospital discharge is not available in these state databases. Although late complications appear to occur after CEA and CAS, the frequency of late events appears similar with both procedures, suggesting comparisons based on hospital outcomes are valid. 27 
CONCLUSIONS
This analysis brings to question the current role of CAS for the treatment of both asymptomatic and symptomatic carotid atherosclerosis. Perioperative stroke/mortality rates of 8.3% for CAS vs 4.6% for CEA in symptomatic patients raises questions about the utility of CAS in these patients. For asymptomatic patients, the nearly equivalent rate of combined stroke and death of 2.4% for CAS vs 1.9% for CEA leads us to hypothesize that the less invasive approach may be an acceptable option in these patients. 141, 142, 143, 144, 145, 146, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 162, 163, 164, 165, 170, 171, 172, 174, 175, 176, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203 
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